Why the study?
Low-molecular-weight heparins have been the standard of care for treating VTE in cancer patients, and widespread DOAC use has not been adopted.
Do direct oral anticoagulants (DOACs) safely and effectively treat venous thromboembolism or atrial fibrillation in patients with cancer?
Do direct oral anticoagulants (DOACs) safely and effectively treat venous thromboembolism or atrial fibrillation in patients with cancer?
This review highlights emerging evidence from recent trials suggesting DOACs may be a viable alternative to low-molecular-weight heparins for treating VTE in cancer patients.
May support DOAC use for cancer-associated VTE; leaves open optimal selection and AF safety data.
PURPOSE: This review summarizes the available evidence concerning direct oral anticoagulant (DOAC) use to treat venous thromboembolism (VTE) in patients with cancer as well as pertinent safety data on the use of DOACs in patients with both cancer and atrial fibrillation. SUMMARY: The introduction of DOACs into clinical practice changed the way thrombotic complications are managed and prevented in diverse patient populations, including VTE and atrial fibrillation. Low-molecular-weight heparins have been the standard of care for treating VTE in cancer patients due to superiority over vitamin K antagonists in preventing recurrent VTE. Therefore, widespread DOAC use for VTE in patients with active cancer has not been adopted. CONCLUSION: Recent randomized clinical trials (SELECT-D, Hokusai VTE Cancer) have provided evidence that DOACs may have a role in treating VTE in cancer patients.
No takes yet. Share an insight, caveat, or question.
Bossaer et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: